Boston Stem Cell LLC is categorized under Wholesale Pharmaceutical Products in Acton, MA and active since 2011.
Boston Stem Cell LLC was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Wholesale Pharmaceutical Products business, which does work in the B2B market, and is classified as a Wholesale Pharmaceutical Products, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact John D Mcneish at the company’s single location by writing to 491 Main St, Acton, Massachusetts MA 01720 or by phoning (860) 235-2228. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Boston Stem Cell LLC |
| Contact Person: | John D Mcneish |
| Address: | 491 Main St, Acton, Massachusetts 01720 |
| Phone Number: | (860) 235-2228 |
| Website Address: | bostonstem.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Wholesale Pharmaceutical Products |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Boston Stem Cell LLC was started in 2011 to provide professional Wholesale Pharmaceutical Products under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact John D Mcneish for inquiries that concern Boston Stem Cell LLC by calling the company number (860) 235-2228, as your correspondence is most welcome. Additionally, the physical location of the single location of Boston Stem Cell LLC can be found at the coordinates 42.48647,-71.432245 as well as the street address 491 Main St in Acton, Massachusetts 01720.
For its online presence, you may visit Boston Stem Cell LLC’s website at bostonstem.com and engage with its social media outlets through on Twitter and on Facebook.